<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118196</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000433313</org_study_id>
    <secondary_id>MUSC-MDS2773</secondary_id>
    <secondary_id>MUSC-15348</secondary_id>
    <nct_id>NCT00118196</nct_id>
  </id_info>
  <brief_title>Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving azacitidine together with arsenic&#xD;
      trioxide works in treating patients with myelodysplastic syndromes or chronic myelomonocytic&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with myelodysplastic syndromes or chronic&#xD;
           myelomonocytic leukemia treated with azacitidine and arsenic trioxide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine time to treatment failure in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the tolerability and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine progression-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This a multicenter, non-randomized, open-label, study.&#xD;
&#xD;
      Patients receive azacitidine subcutaneously once daily on days 1-5 and arsenic trioxide IV&#xD;
      over 1-2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment repeats every 28 days for 4&#xD;
      courses in the absence of disease progression or unacceptable toxicity. Patients are&#xD;
      evaluated for response on day 113 (week 17). Patients with disease progression or no response&#xD;
      are removed from the study. Patients achieving a complete response (CR) receive 2 additional&#xD;
      courses of therapy and then undergo observation. Patients achieving a partial response&#xD;
      receive 2 additional courses of therapy and then receive arsenic trioxide alone twice weekly&#xD;
      in the absence of CR, disease progression, or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for at least 1&#xD;
      year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-41 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to limited resources available to conduct study&#xD;
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 11, 2006</completion_date>
  <primary_completion_date type="Actual">August 11, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (overall and confirmed) as measured by International Working Group (IWG) standardized criteria for MDS at day 113 and then every 4 weeks until completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure as assessed by the Kaplan-Meier method at completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival as assessed by the Kaplan-Meier method at completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by the Kaplan-Meier method and NCI-CTCAE version 3.0 during treatment until 30 days after completion of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of myelodysplastic syndrome or chronic myelomonocytic leukemia&#xD;
&#xD;
          -  International Prognostic Scoring System (IPSS) score ≥ intermediate-1&#xD;
&#xD;
               -  Low IPSS score allowed provided patient meets ≥ 1 of the following criteria:&#xD;
&#xD;
                    -  Platelet count ≤ 50,000/mm^3&#xD;
&#xD;
                    -  Required platelet or packed red cell transfusions within the past 4 weeks&#xD;
&#xD;
                    -  Neutropenic (i.e., absolute neutrophil count &lt; 1,000/mm^3) AND has&#xD;
                       infections requiring antibiotic treatment&#xD;
&#xD;
          -  No prior leukemia or refractory anemia with excess blasts in transformation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Baseline QTc &lt; 500 msec&#xD;
&#xD;
          -  QTc interval &lt; 460 msec with potassium &gt; 4.0 mEq/L and magnesium &gt; 1.8 mg/L&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to study drugs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other malignancy within the past 12 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior administration of any of the following:&#xD;
&#xD;
               -  Interferon&#xD;
&#xD;
               -  Filgrastim (G-CSF), sargramostim (GM-CSF), epoetin alfa, or other hematopoietic&#xD;
                  cytokines&#xD;
&#xD;
               -  Thalidomide or thalidomide analogs&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior arsenic trioxide or azacitidine&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior steroids&#xD;
&#xD;
          -  No concurrent androgenic steroids&#xD;
&#xD;
               -  Concurrent steroids for adrenal failure or as prophylaxis for nausea allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior retinoids&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert K. Stuart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

